Long-term outcomes of avelumab maintenance in older patients with advanced urothelial carcinoma in Japan from the JAVEMACS study

The retrospective JAVEMACS chart review study described outcomes of avelumab first-line maintenance for patients with locally advanced/metastatic urothelial carcinoma without progression after platinum-based chemotherapy (PBC) in Japanese real-world practice. This post hoc exploratory analysis compared outcomes by age at avelumab initiation (<​75 vs. ≥​75 [main] and <​80 vs. ≥​80 years [supportive]). Stabilized inverse probability of treatment weighting estimated covariate-standardized associations; causal inference was not intended. Overall survival (OS) and progression-free survival (PFS) were assessed using unadjusted and weighted Kaplan-Meier and Cox models. Among 349 patients, 206 (59.0%) and 143 (41.0%) were <​75 and ≥​75 years, respectively. In the complete-case propensity score analysis set (n = 267), balance improved for most covariates, but some residual imbalance remained and overlap was limited. In the main weighted analyses, there were no statistically significant age-group differences in OS (HR 0.832, 95% CI 0.554–1.248; p = 0.372) and PFS (HR 0.794, 95% CI 0.577–1.093; p = 0.156); supportive results were also not statistically significant. These exploratory observations do not establish equivalence or an age-specific treatment effect, and interpretations should consider the retrospective design, complete-case weighting, limited overlap, and residual confounding. These findings provide descriptive long-term outcomes for older patients receiving avelumab maintenance in Japanese practice.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-20
DOI
https://doi.org/10.1038/s41598-026-79463-5
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Long-term outcomes of avelumab maintenance in older patients with advanced urothelial carcinoma in Japan from the JAVEMACS study

Naotaka Nishiyama, Eiji Kikuchi, Takahito Negishi, Mizuki Kobayashi et al.
8 links
Scientific Reports
Bladder and Urothelial Cancer Treatments
article

Long-term outcomes of avelumab maintenance in older patients with advanced urothelial carcinoma in Japan from the JAVEMACS study

Naotaka Nishiyama, Eiji Kikuchi, Takahito Negishi, Mizuki Kobayashi, Sei Naito, Takuto Hara, Suguru Shirotake, Rikiya Taoka, Toru Sakatani, Junya Furukawa, Masaomi Ikeda, Kiyoaki Nishihara, Junji Yatsuda, Noriyoshi Miura, Takashige Abe, Daiki Ikarashi, Norihiko Kawamura, Naoya Masumori, Atsuko Fujihara, Michihiro Shono, Kan Yonemori, Masayoshi Nagata, Tohru Nakagawa, Takashi Kobayashi, Kiyohide Fujimoto, Shingo Hatakeyama, Nozomi Hayakawa, Yuki Endo, Hiroshi Kitamura, Kazutoshi Fujita
article en

Abstract

The retrospective JAVEMACS chart review study described outcomes of avelumab first-line maintenance for patients with locally advanced/metastatic urothelial carcinoma without progression after platinum-based chemotherapy (PBC) in Japanese real-world practice. This post hoc exploratory analysis compared outcomes by age at avelumab initiation (<​75 vs. ≥​75 [main] and <​80 vs. ≥​80 years [supportive]). Stabilized inverse probability of treatment weighting estimated covariate-standardized associations; causal inference was not intended. Overall survival (OS) and progression-free survival (PFS) were assessed using unadjusted and weighted Kaplan-Meier and Cox models. Among 349 patients, 206 (59.0%) and 143 (41.0%) were <​75 and ≥​75 years, respectively. In the complete-case propensity score analysis set (n = 267), balance improved for most covariates, but some residual imbalance remained and overlap was limited. In the main weighted analyses, there were no statistically significant age-group differences in OS (HR 0.832, 95% CI 0.554–1.248; p = 0.372) and PFS (HR 0.794, 95% CI 0.577–1.093; p = 0.156); supportive results were also not statistically significant. These exploratory observations do not establish equivalence or an age-specific treatment effect, and interpretations should consider the retrospective design, complete-case weighting, limited overlap, and residual confounding. These findings provide descriptive long-term outcomes for older patients receiving avelumab maintenance in Japanese practice.

Scientific Reports
Kurume University (JP), Yamagata University (JP), Sapporo Medical University (JP), Hirosaki University (JP), St. Marianna University School of Medicine (JP), Iwate Medical University (JP), Kagawa University (JP), Akita University (JP), Hokkaido University (JP), Kyoto University (JP), Juntendo University (JP), Kyoto Prefectural University of Medicine (JP), National Hospital Organization Kyushu Cancer Center (JP), Merck Biopharma Co., Ltd. (Japan) (JP), Saitama International Medical Center (JP), Osaka International Cancer Institute (JP), Nippon Medical School Hospital (JP), University of Toyama (JP), Ehime University (JP), National Cancer Center Hospital (JP), Kitasato University (JP), Nara Medical University (JP), Kobe University (JP), Saitama Medical University (JP), Teikyo University (JP), Kindai University (JP), Tokushima University (JP), Kumamoto University (JP)
Merck KGaA
Good health and well-being
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon